T
Tarsus Pharmaceuticals, Inc.
TARS · NASDAQ · Healthcare · 3.0B
Closing price
$73.16
+1.31% · last session
Graham & Buffett's criteria
published figures · last financial year
Price / earningsP/E
—
Price / net assetsP/B
8.9×
Enterprise value / EBITDAEV/EBITDA
-55.3×
Free cash flow yieldFCF yield
-0.7%
Return on equityROE
-19.3%
Operating margin
-15.7%
Net debt / EBITDAbalance-sheet strength
1.7×
Interest coverage
-7.9×
How we read it
an educational summary · not advice
Figures provided for information and education — they do not constitute personalized investment advice. Investing carries a risk of capital loss.